HomeAI · summaries
Storia in 2 fonti
Celcuity aims for broad FDA approval after positive breast cancer readout
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Celcuity aims for broad FDA approval after positive breast cancer readout
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
- ·
benzinga.com
What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.